01:21 PM EDT, 10/29/2024 (MT Newswires) -- Eli Lilly ( LLY ) reported Tuesday positive results from its phase 3b study of Kisunla in patients with early symptomatic Alzheimer's disease.

The study showed a reduction in imaging abnormalities with edema/effusion at the 24-week primary endpoint for people receiving a slightly modified titration of donanemab in adults with early symptomatic Alzheimer's disease, the firm said.

A change in the initiation of donanemab dosing, shifting one vial of donanemab from the first infusion to the third infusion, lowered ARIA-E to 14% compared to 24% in patients receiving the standard dosing regimen used in the pivotal Phase 3 clinical trial, the company said.

Eli Lilly ( LLY ) said it is in discussions with global regulators to submit the study results for a potential label update for Kisunla.

Price: 901.10, Change: +5.51, Percent Change: +0.62